CAR-T Manufacturing: Centralized Vs. Hybrid Models

The rapid evolution of autologous CAR-T cell therapies is shifting industry focus from clinical validation to operational scalability. Selecting the right manufacturing infrastructure—centralized or hybrid—is a critical strategic choice that influences clinical timelines, product quality, regulatory success, and cost of goods. Centralized models offer high operational control, simplified regulatory compliance, optimized equipment usage, and a single Quality Management System. However, they rely heavily on global cryogenic logistics, where transit delays or temperature excursions can extend vein-to-vein timelines and compromise patient outcomes. Hybrid models combine a central hub with regional facilities closer to clinical sites, drastically reducing transit times and offering operational redundancy. However, regional execution presents technical hurdles, including process comparability, human variability, and analytical harmonization across sites.

See how early planning allows developers to build flexible, hybrid-ready architectures that scale seamlessly as commercial demand grows.